Advertisement
Advertisement

VTVT

VTVT logo

vTv Therapeutics Inc. Class A Common Stock

35.37
USD
Sponsored
+0.76
+2.20%
Aug 07, 15:59 UTC -4
Closed
exchange

Pre-Market

35.17

-0.20
-0.56%

vTv Therapeutics Inc. Class A Common Stock Profile

About

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Info & Links

CEO

Paul J. Sekhri

Headquarters

3980 PREMIER DR, SUITE 310
HIGH POINT, NC 27265, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.vtvtherapeutics.com

Auditor

Ernst & Young LLP

Share holders

46

Employees

26

vTv Therapeutics Inc. Class A Common Stock Statistics

Valuation Measures

Market Capitalization2

138.53M

Enterprise Value

51.89M

Enterprise Value/EBITDA(ttm)

-5.61

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.55

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

16.38%

Return on Equity(ttm)

-6.34%

Return on Invested Capital(ttm)

-15.52%

Return on Assets(ttm)

-4.95%

Income Statement

Revenue(ttm)

36.84M

Revenue Per Share(ttm)

9.32

Gross Profit(ttm)

36.84M

EBITDA(ttm)3

-9.25M

Net Income Available to Common(ttm)

-4.76M

Diluted EPS(ttm)

-1.06

Share Statistics

Beta (5Y Monthly)

0.28

52-Week Change

152.64%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

3.95M

Dividend Yield

0.00%

Float4

3.70M

% Held by Insiders

5.99%

% Held by Institutions

17.51%

Balance Sheet

Total Cash(mrq)

86.64M

Total Cash Per Share(mrq)

21.91

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.48%

Quick Ratio(mrq)

14.36%

Book Value Per Share(mrq)

19.96

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.18

Free Cash Flow(ytd)

-2.29M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement